Abstract
EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
